TELUS-INT
2.3.2021 12:02:14 CET | Business Wire | Press release
TELUS International (NYSE and TSX: TIXT), a leading digital customer experience (CX) innovator that designs, builds, and delivers next-generation solutions for global and disruptive brands, today announced the final completion of the December 31, 2020 closing of its previously announced acquisition of a 100% interest in Lionbridge AI, following the clearance of the acquisition by the Committee on Foreign Investment in the United States (CFIUS). Lionbridge AI is one of only two globally-scaled, managed training data and data annotation services and platform providers in the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210302005381/en/
“The integration of digital CX services and solutions, powered by artificial intelligence (AI) and machine learning, has quickly become a key differentiator for brands in today’s experience economy, driving significant benefits by way of increased customer loyalty and satisfaction, larger market share and revenue growth,” said Jeff Puritt, president and CEO of TELUS International. “The caveat is that these next-gen capabilities, such as intelligent chatbots, voice-activated virtual assistants and optimized search engines, must be trained on large amounts of accurate, reliable and unbiased data in order to be effective. With Lionbridge AI integration activities well-underway since the start of the year, TELUS International is able to meet these heightened and critical requirements while simultaneously meeting our clients’ digital transformation needs across the full customer experience value chain, ultimately defining a new market category at the intersection of digital IT and digital CX.”
Lionbridge AI is a leading and global provider of scalable data annotation services for text, images, videos, and audio. The company sources multilingual training data in more than 300 languages and dialects to build premium, ground truth data for some of the world’s largest technology companies in social media, search, retail and mobile. Lionbridge AI has also developed a proprietary data annotation platform that is used in combination with a crowdsourced community of one million professional annotators, qualified linguists and in-country language speakers across six continents.
“As part of the TELUS International family, we are already seizing the significant opportunities inherent in the merging of our firms’ capabilities and services. By integrating our digital CX and AI solutions, we are further deepening the high-value relationships we enjoy with some of the world’s largest and fastest growing companies across many industries,” said Ed Jay, president, Lionbridge AI. “We are excited to build upon our momentum in the market as the prevalence of AI-powered technologies and solutions continues to grow. Together as a unified company, we will remain focused on delivering the highest-quality AI training data and crowdsourced talent to help the brands we support deliver the best, most engaging and human-informed AI experiences and initiatives to consumers.”
“Adjacent to supporting our clients’ development and deployment of AI algorithms comes the responsibility to mitigate harmful biases that could have far-reaching ethical implications for consumers and society as a whole,” continued Puritt. “Our team’s commitment in this regard includes fostering a diverse, experienced and tenured team of human annotators, ensuring the optimum demographic distribution for each project, and establishing clear guidelines that focus on uniformity and consistency of data labeling, but that also consider the flexibility required to address the inevitable ambiguity of real world data.”
Rothschild & Co served as financial advisors and Shearman & Sterling LLP served as legal counsel to TELUS International for this transaction.
About TELUS International
TELUS International (NYSE and TSX: TIXT) designs, builds and delivers next-generation digital solutions to enhance the customer experience (CX) for global and disruptive brands. The company’s services support the full lifecycle of its clients’ digital transformation journeys and enable them to more quickly embrace next-generation digital technologies to deliver better business outcomes. TELUS International’s integrated solutions and capabilities span digital strategy, innovation, consulting and design, digital transformation and IT lifecycle solutions, data annotation and intelligent automation, and omnichannel CX solutions that include content moderation, trust and safety solutions and other managed solutions. Fueling all stages of company growth, TELUS International partners with brands across high growth industry verticals, including tech and games, communications and media, eCommerce and fintech, healthcare, and travel and hospitality. Learn more at: telusinternational.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005381/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
China's ~$900B Live-Commerce Market Now Approaches US E-Commerce Scale17.7.2026 12:30:00 CEST | Press release
The consumer habits reshaping global retail were built in the East — and most Western shoppers haven't yet adopted them. NIQ report shows that brands still treating live, social, and quick commerce as "emerging" risk being left behind. The center of gravity in global retail has shifted East. The formats now driving the fastest growth in global retail (live shopping, social commerce, and delivery in minutes) were pioneered and scaled in Asia, and most Western consumers have yet to adopt them. According to NIQ (NYSE: NIQ), a leading consumer intelligence company, in its global report The Commerce Revolution: Where East Meets West, the gap between East and West is still vast. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717253489/en/ China´s USD 900bn live shopping boom now approaches the scale of the US E-commerce The scale is already substantial. China's live-commerce market alone was worth roughly $900 billion in 2025,
Ant International’s Alipay+ Connects Argentina's National QR Payment Scheme via PVS,Enabling for Cross-Border Digital Payment Nationwide at Millions of Merchants17.7.2026 12:17:00 CEST | Press release
Alipay+, a global digital payment gateway under Ant International, today announced that it will enable global travellers to make QR code payments at millions of merchants across Argentina through integration with the country's national QR payment scheme Transferencias 3.0, in partnership with PVS, a fintech company specialized in developing customized payment solutions in Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717276406/en/ By connecting to Argentina's national QR payment scheme, Alipay+ now enables global travellers in the country to make convenient QR code payments at merchants nationwide. This service helps to enhance global travellers' travel experiences in Argentina, allowing them to pay seamlessly at restaurants, malls and tourist attractions. Using an Alipay+ partner payment app, they can now scan the national QR code displayed at all merchants to make cross-border payments across Argentina,
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
